Massive south african trial tests 'Treat All' strategy to stop HIV

NCT ID NCT01509508

Completed Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study in South Africa tested whether offering HIV treatment to everyone right after diagnosis, instead of waiting until their immune system weakened, could reduce new HIV infections across entire communities. Over 28,000 people from 22 communities took part. The idea is that treating people early lowers the amount of virus in their body, making it much less likely to pass HIV to others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atripla (tenofovir/emtricitabine/efavirenz)
What this could lead to: If successful, this strategy could show that immediate HIV treatment for everyone diagnosed dramatically lowers new infections in a community, pointing toward a way to control the epidemic.
What could go wrong: This is a large trial, but results depend on real-world uptake and adherence. The strategy may not work as well in other settings or populations, and side effects from lifelong medication are a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

Hlabisa Hospital

Hlabisa, KwaZulu-Natal, 3937, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.